Alexion Pharmaceuticals (Alexion Pharmaceuticals) Days Sales Outstanding : 80.36 (As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Days Sales Outstanding?

Alexion Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2021 was $1,441 Mil. Alexion Pharmaceuticals's Revenue for the three months ended in Mar. 2021 was $1,637 Mil. Hence, Alexion Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2021 was 80.36.

The historical rank and industry rank for Alexion Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.69 Med: 76.01 Max: 96.21
Current: 82.04

During the past 13 years, Alexion Pharmaceuticals's highest Days Sales Outstanding was 96.21. The lowest was 67.69. And the median was 76.01.

ALXN's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 71.97 vs ALXN: 82.04

Alexion Pharmaceuticals's Days Sales Outstanding declined from Mar. 2020 (81.74) to Mar. 2021 (80.36).

Alexion Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Alexion Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Days Sales Outstanding Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Days Sales Outstanding

Get a 7-Day Free Trial

69.98

70.72

72.84

79.18

79.75

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Days Sales Outstanding	Get a 7-Day Free Trial															81.74	85.82	80.68	81.58	80.36

Competitive Comparison of Alexion Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Alexion Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alexion Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Days Sales Outstanding falls into.

Alexion Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Alexion Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as

	Days Sales Outstanding (A: Dec. 2020 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2019 )	+	Accounts Receivable (A: Dec. 2020 ))	/	count )	/	Revenue (A: Dec. 2020 )	*	Days in Period
=	( (1243.2	+	1409.3)	/	2 )	/	6069.9	*	365
=	1326.25					/	6069.9	*	365
=	79.75

Alexion Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2021 is calculated as:

	Days Sales Outstanding (Q: Mar. 2021 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2020 )	+	Accounts Receivable (A: Mar. 2021 ))	/	count )	/	Revenue (A: Mar. 2021 )	*	Days in Period
=	( (1409.3	+	1473)	/	2 )	/	1636.5	*	365 / 4
=	1441.15					/	1636.5	*	365 / 4
=	80.36

Alexion Pharmaceuticals (NAS:ALXN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Alexion Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974